ADPT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Adaptive Biotechnologies Corp (ADPT) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has shown strong revenue growth and positive analyst sentiment, the recent insider selling, declining net income, and lack of significant trading signals suggest a cautious approach. The stock's technical indicators are neutral, and options data does not indicate strong bullish sentiment. Holding for now is the recommended action.
The MACD is positive but contracting, indicating weakening momentum. RSI is neutral at 44.497, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock is trading near its pivot level (15.898), with resistance at 16.737 and support at 15.059. Overall, the technical indicators suggest a neutral trend.
Revenue growth of 51.04% YoY in Q4
Gross margin improvement to 73.98%, up 21.12% YoY.
Analysts have raised price targets and maintain Buy ratings, citing strong fundamentals and growth drivers such as EMR integrations and new indications.
Insider selling by Chad Robins, who sold significant shares recently.
Net income dropped by 59.70% YoY, and EPS declined by 60.87% YoY in Q4
Stock trend analysis suggests a 70% chance of a short-term decline (-3.16% in the next week).
In Q4 2025, revenue increased by 51.04% YoY to $71.68 million, and gross margin improved to 73.98%. However, net income dropped by 59.70% YoY to -$13.58 million, and EPS declined by 60.87% YoY to -0.09, indicating profitability challenges despite revenue growth.
Analysts are bullish, with multiple firms raising price targets to $21-$22 and maintaining Buy or Overweight ratings. They cite strong Q4 results, raised guidance, and growth drivers as reasons for optimism.
